Lihi Eder1, Ruth Croxford2, Aaron M Drucker1, Arielle Mendel3, Bindee Kuriya4, Zahi Touma5, Sindhu R Johnson6, Richard Cook7, Sasha Bernatsky3, Nigil Haroon8, Jessica Widdifield9. 1. University of Toronto, Toronto, Ontario, Canada. 2. ICES, Toronto, Ontario, Canada. 3. McGill University, Montreal, Quebec, Canada. 4. Sinai Health System, University of Toronto, Toronto, Ontario, Canada. 5. Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. 6. Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. 7. University of Waterloo, Waterloo, Ontario, Canada. 8. Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. 9. Sunnybrook Research Institute, ICES, University of Toronto, Toronto, Ontario, Canada.
Abstract
OBJECTIVE: To investigate the incidence of and factors associated with SARS-CoV-2 testing and infection in immune-mediated inflammatory disease (IMID) patients versus matched non-IMID comparators from the general population. METHODS: We conducted a population-based, matched cohort study among adult residents from Ontario, Canada, from January 2020 to December 2020. We created cohorts for the following IMIDs: rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, ankylosing spondylitis, systemic autoimmune rheumatic diseases, multiple sclerosis (MS), iritis, inflammatory bowel disease (IBD), polymyalgia rheumatica, and vasculitis. Each patient was matched with 5 patients without IMIDs based on sociodemographic factors. We estimated the incidence of SARS-CoV-2 testing and infection in IMID patients and non-IMID patients. Multivariable logistic regressions assessed odds of SARS-CoV-2 infection. RESULTS: We studied 493,499 patients with IMIDs and 2,466,946 patients without IMIDs. Patients with IMIDs were more likely to have at least 1 SARS-CoV-2 test versus patients without IMIDs (27.4% versus 22.7%), but the proportion testing positive for SARS-CoV-2 was identical (0.9% in both groups). Overall, IMID patients had 20% higher odds of being tested for SARS-CoV-2 (odds ratio 1.20 [95% confidence interval 1.19-1.21]). The odds of SARS-CoV-2 infection varied across IMID groups but was not significantly elevated for most IMID groups compared with non-IMID comparators. The odds of SARS-CoV-2 infection was lower in IBD and MS and marginally higher in RA and iritis. CONCLUSION: Patients across all IMIDs were more likely to be tested for SARS-CoV-2 versus those without IMIDs. The risk of SARS-CoV-2 infection varied across disease subgroups.
OBJECTIVE: To investigate the incidence of and factors associated with SARS-CoV-2 testing and infection in immune-mediated inflammatory disease (IMID) patients versus matched non-IMID comparators from the general population. METHODS: We conducted a population-based, matched cohort study among adult residents from Ontario, Canada, from January 2020 to December 2020. We created cohorts for the following IMIDs: rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, ankylosing spondylitis, systemic autoimmune rheumatic diseases, multiple sclerosis (MS), iritis, inflammatory bowel disease (IBD), polymyalgia rheumatica, and vasculitis. Each patient was matched with 5 patients without IMIDs based on sociodemographic factors. We estimated the incidence of SARS-CoV-2 testing and infection in IMID patients and non-IMID patients. Multivariable logistic regressions assessed odds of SARS-CoV-2 infection. RESULTS: We studied 493,499 patients with IMIDs and 2,466,946 patients without IMIDs. Patients with IMIDs were more likely to have at least 1 SARS-CoV-2 test versus patients without IMIDs (27.4% versus 22.7%), but the proportion testing positive for SARS-CoV-2 was identical (0.9% in both groups). Overall, IMID patients had 20% higher odds of being tested for SARS-CoV-2 (odds ratio 1.20 [95% confidence interval 1.19-1.21]). The odds of SARS-CoV-2 infection varied across IMID groups but was not significantly elevated for most IMID groups compared with non-IMID comparators. The odds of SARS-CoV-2 infection was lower in IBD and MS and marginally higher in RA and iritis. CONCLUSION: Patients across all IMIDs were more likely to be tested for SARS-CoV-2 versus those without IMIDs. The risk of SARS-CoV-2 infection varied across disease subgroups.
Authors: Jessica Widdifield; Noah M Ivers; Jacqueline Young; Diane Green; Liisa Jaakkimainen; Debra A Butt; Paul O'Connor; Simon Hollands; Karen Tu Journal: Mult Scler Date: 2014-11-12 Impact factor: 6.312
Authors: Kevin A Brown; Aaron Jones; Nick Daneman; Adrienne K Chan; Kevin L Schwartz; Gary E Garber; Andrew P Costa; Nathan M Stall Journal: JAMA Intern Med Date: 2021-02-01 Impact factor: 21.873
Authors: Linwei Wang; Huiting Ma; Kristy C Y Yiu; Andrew Calzavara; David Landsman; Linh Luong; Adrienne K Chan; Rafal Kustra; Jeffrey C Kwong; Marie-Claude Boily; Stephen Hwang; Sharon Straus; Stefan D Baral; Sharmistha Mishra Journal: CMAJ Open Date: 2020-10-09
Authors: Eric I Benchimol; Astrid Guttmann; David R Mack; Geoffrey C Nguyen; John K Marshall; James C Gregor; Jenna Wong; Alan J Forster; Douglas G Manuel Journal: J Clin Epidemiol Date: 2014-04-26 Impact factor: 6.437
Authors: William W Eaton; Marianne G Pedersen; Hjördís Osk Atladóttir; Patricia E Gregory; Noel R Rose; Preben Bo Mortensen Journal: Immunol Res Date: 2010-07 Impact factor: 2.829
Authors: Xabier Michelena; Helena Borrell; Mireia López-Corbeto; María López-Lasanta; Estefanía Moreno; María Pascual-Pastor; Alba Erra; Mayte Serrat; Esther Espartal; Susana Antón; Gustavo Adolfo Añez; Raquel Caparrós-Ruiz; Andrea Pluma; Ernesto Trallero-Araguás; Mireia Barceló-Bru; Miriam Almirall; Juan José De Agustín; Jordi Lladós; Antonio Julià; Sara Marsal Journal: Semin Arthritis Rheum Date: 2020-05-16 Impact factor: 5.532
Authors: Kamil Malikov; Qing Huang; Shengli Shi; Nathan M Stall; Ashleigh R Tuite; Michael P Hillmer Journal: J Am Med Dir Assoc Date: 2020-12-19 Impact factor: 4.669
Authors: Jessica Widdifield; Jeffrey C Kwong; Simon Chen; Lihi Eder; Eric I Benchimol; Gilaad G Kaplan; Carol Hitchon; J Antonio Aviña-Zubieta; Diane Lacaille; Hannah Chung; Sasha Bernatsky Journal: Lancet Rheumatol Date: 2022-04-14